{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:51:27Z","timestamp":1792929087145,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"Importance<\/jats:title>Serious cutaneous adverse drug reactions (cADRs) are potentially life-threatening drug hypersensitivity reactions involving the skin and internal organs. Antibiotics are a recognized cause of these reactions, but no studies have compared relative risks across antibiotic classes.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To explore the risk of serious cADRs associated with commonly prescribed oral antibiotics, and to characterize outcomes of patients hospitalized for them.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Nested case-control study using population-based linked administrative datasets among adults aged 66 years or older who received at least 1 oral antibiotic between 2002 and 2022 in Ontario, Canada. Cases were those who had an emergency department (ED) visit or hospitalization for serious cADRs within 60 days of the prescription, and each case was matched with up to 4 controls who did not.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Various classes of oral antibiotics.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Conditional logistic regression estimate of the association between different classes of oral antibiotics and serious cADRs, using macrolides as the reference group.<\/jats:p><\/jats:sec>Results<\/jats:title>During the 20-year study period, we identified 21\u202f758 older adults (median age, 75 years; 64.1% female) who had an ED visit or hospitalization for serious cADRs following antibiotic therapy and 87\u202f025 matched controls who did not. In the primary analysis, sulfonamide antibiotics (adjusted odds ratio [aOR], 2.9; 95% CI, 2.7-3.1) and cephalosporins (aOR, 2.6; 95% CI, 2.5-2.8) were most strongly associated with serious cADRs relative to macrolides. Additional associations were evident with nitrofurantoin (aOR, 2.2; 95% CI, 2.1-2.4), penicillins (aOR, 1.4; 95% CI, 1.3-1.5), and fluoroquinolones (aOR, 1.3; 95% CI, 1.2-1.4). The crude rate of ED visits or hospitalization for cADRs was highest for cephalosporins (4.92 per 1000 prescriptions; 95% CI, 4.86-4.99) and sulfonamide antibiotics (3.22 per 1000 prescriptions; 95% CI, 3.15-3.28). Among the 2852 case patients hospitalized for cADRs, the median length of stay was 6 days (IQR, 3-13 days), 9.6% required transfer to a critical care unit, and 5.3% died in the hospital.<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>Commonly prescribed oral antibiotics are associated with an increased risk of serious cADRs compared with macrolides, with sulfonamides and cephalosporins carrying the highest risk. Prescribers should preferentially use lower-risk antibiotics when clinically appropriate.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2024.11437","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:03:23Z","timestamp":1723129403000},"page":"730","source":"Crossref","is-referenced-by-count":33,"title":["Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions"],"prefix":"10.1001","volume":"332","author":[{"given":"Erika Y.","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology and Allergy, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada"},{"name":"Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Drucker","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Daneman","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Asaf","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyun","family":"Wu","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"},{"name":"Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Division of General Internal Medicine and Clinical Pharmacology and Toxicology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi240079r1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study.","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"21","key":"joi240079r2","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1001\/jama.2014.839","article-title":"Recurrence and mortality following severe cutaneous adverse reactions.","volume":"311","author":"Finkelstein","year":"2014","journal-title":"JAMA"},{"issue":"10106","key":"joi240079r3","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs.","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"joi240079r4","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK.","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"joi240079r5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.anai.2019.08.004","article-title":"Drug-induced severe cutaneous adverse reactions: determine the cause and prevention.","volume":"123","author":"Zhang","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"joi240079r6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"9","key":"joi240079r7","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1093\/jac\/dkab205","article-title":"Measuring the impacts of the Using Antibiotics Wisely campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019.","volume":"76","author":"Rolf von den Baumen","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"joi240079r9","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/cid\/ciu126","article-title":"Severe cutaneous adverse reactions related to systemic antibiotics.","volume":"58","author":"Lin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"joi240079r10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"7","key":"joi240079r11","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.burns.2013.03.011","article-title":"27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents.","volume":"39","author":"Weinand","year":"2013","journal-title":"Burns"},{"issue":"5","key":"joi240079r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026771","article-title":"Factors associated with adverse drug reaction occurrence and prognosis, and their economic impacts in older inpatients in Taiwan: a nested case-control study.","volume":"9","author":"Liao","year":"2019","journal-title":"BMJ Open"},{"issue":"20","key":"joi240079r13","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1001\/jama.2016.16201","article-title":"US emergency department visits for outpatient adverse drug events, 2013-2014.","volume":"316","author":"Shehab","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"joi240079r14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s11606-018-4430-x","article-title":"National estimates of emergency department visits for antibiotic adverse events among adults\u2014United States, 2011-2015.","volume":"33","author":"Geller","year":"2018","journal-title":"J Gen Intern Med"},{"key":"joi240079r15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fphar.2020.00412","article-title":"Italian emergency department visits and hospitalizations for outpatients\u2019 adverse drug events: 12-year active pharmacovigilance surveillance (the MEREAFaPS Study).","volume":"11","author":"Lombardi","year":"2020","journal-title":"Front Pharmacol"},{"issue":"11","key":"joi240079r16","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States.","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"12","key":"joi240079r18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"joi240079r19","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"joi240079r20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current perspectives on severe drug eruption.","volume":"61","author":"Zhang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"joi240079r21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer.","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"8","key":"joi240079r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221130","article-title":"Development of an electronic medical record-based algorithm to identify patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan.","volume":"14","author":"Fukasawa","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"joi240079r23","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s11096-018-0625-9","article-title":"Epidemiology of drug hypersensitivity reactions using 6-year national health insurance claim data from Korea.","volume":"40","author":"Han","year":"2018","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"joi240079r24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/ajd.2014.55.issue-4","article-title":"Which patients with dermatological conditions are admitted via the emergency department?","volume":"55","author":"Lai-Kwon","year":"2014","journal-title":"Australas J Dermatol"},{"issue":"4","key":"joi240079r25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.alit.2016.04.001","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS): 11 years retrospective study in Thailand.","volume":"65","author":"Hiransuthikul","year":"2016","journal-title":"Allergol Int"},{"issue":"4","key":"joi240079r26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11096-009-9300-5","article-title":"Prescribing errors in patients with documented drug allergies: comparison of ICD-10 coding and written patient notes.","volume":"31","author":"Benkhaial","year":"2009","journal-title":"Pharm World Sci"},{"issue":"4","key":"joi240079r27","doi-asserted-by":"publisher","first-page":"E878","DOI":"10.9778\/cmajo.20170100","article-title":"A decade of outpatient antimicrobial use in older adults in Ontario: a descriptive study.","volume":"5","author":"Tan","year":"2017","journal-title":"CMAJ Open"},{"issue":"7","key":"joi240079r28","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson Syndrome and toxic epidermal necrolysis in United States adults.","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"4","key":"joi240079r29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/ACI.0000000000000545","article-title":"Drug hypersensitivity in HIV infection.","volume":"19","author":"Peter","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"joi240079r30","doi-asserted-by":"publisher","first-page":"E263","DOI":"10.1503\/cmaj.121383","article-title":"The effect of socioeconomic status on access to primary care: an audit study.","volume":"185","author":"Olah","year":"2013","journal-title":"CMAJ"},{"key":"joi240079r31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fpubh.2020.00231","article-title":"Socioeconomic status and access to healthcare: interrelated drivers for healthy aging.","volume":"8","author":"McMaughan","year":"2020","journal-title":"Front Public Health"},{"issue":"11","key":"joi240079r32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"joi240079r33","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2278685","article-title":"Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events.","author":"Zhou","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"joi240079r34","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/bcp.2011.72.issue-6","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"joi240079r35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaci.2014.07.062","article-title":"Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis.","volume":"135","author":"Macy","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"joi240079r36","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jaip.2019.11.035","article-title":"Adverse reactions associated with penicillins, carbapenems, monobactams, and clindamycin: a retrospective population-based study.","volume":"8","author":"Liang","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"joi240079r37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.archger.2009.02.013","article-title":"Prevalence and factors associated with urinary tract infections (UTIs) in very old women.","volume":"50","author":"Eriksson","year":"2010","journal-title":"Arch Gerontol Geriatr"},{"issue":"5","key":"joi240079r38","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"joi240079r39","doi-asserted-by":"publisher","DOI":"10.2217\/ahe.13.38","article-title":"Urinary tract infection in older adults.","volume":"9","author":"Rowe","year":"2013","journal-title":"Aging health"},{"key":"joi240079r40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949520","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed\/MEDLINE case reports from 1980 to 2020.","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"joi240079r41","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2019.12.025","article-title":"Association of HLA-A*11:01 with sulfonamide-related severe cutaneous adverse reactions in Japanese patients.","volume":"140","author":"Nakamura","year":"2020","journal-title":"J Invest Dermatol"},{"key":"joi240079r8","unstructured":"Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System\u2014Report 2016. Accessed June 13, 2024. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/drugs-health-products\/antibiotic-resistance-antibiotique\/antibiotic-resistance-antibiotique-2016-eng.pdf"},{"key":"joi240079r17","unstructured":"Government of Ontario. Ontario Demographic Quarterly: highlights of first quarter: learn about key facts and figures of the province\u2019s demographics for the first quarter of 2023. Accessed June 13, 2024. https:\/\/www.ontario.ca\/page\/ontario-demographic-quarterly-highlights-first-quarter"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2822097\/jama_lee_2024_oi_240079_1724442757.24071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:01:37Z","timestamp":1725375697000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2822097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.11437","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}